1312784-58-9

Basic information

• Product Name: tert-butyl 4-aMino-4-(2-hydroxyethyl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-aMino-4-(2-hydroxyethyl)piperidine-1-carboxylate
• CAS NO: 1312784-58-9
• Molecular Formula: C12H24N2O3
• Molecular Weight: 244.33056
• Mol File: 1312784-58-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-aMino-4-(2-hydroxyethyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-aMino-4-(2-hydroxyethyl)piperidine-1-carboxylate(1312784-58-9)
• EPA Substance Registry System: tert-butyl 4-aMino-4-(2-hydroxyethyl)piperidine-1-carboxylate(1312784-58-9)

Safety Data

• Hazardous Substances Data: 1312784-58-9(Hazardous Substances Data)

Upstream product

• 1333222-34-6 4-amino-4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 362703-57-9 tert-butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate 

Downstream Products

• 1180112-41-7 1,7-diazaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester 

Relevant articles and documents

Preparation method of tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate and oxalate thereof

The invention relates to the field of synthesis of medical intermediates, and particularly discloses tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate and oxalate thereof. The preparation method of tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate comprises the following steps: by taking N-tert-butyloxycarbonyl-4-piperidone, ethyl hydrogen malonate and ammonium acetate as initial raw materials, sequentially carrying out Mannich reaction, reduction reaction, halogenation, cyclization reaction and purification to obtain purified tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate. The preparation method disclosed by the invention is simple to operate and suitable for industrial mass production.

PROTEIN TYROSINE PHOSPHATASE INHIBITORS

Compounds of Formula la or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases in the view of their ability to inhibit SHP2. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.